Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16650740 | 1.00 | BRD4 (0.69) | BRD4BRDT | |
| SCHEMBL17702533 | 0.94 | BRD4 (0.63) | BRD4BRDT | |
| SCHEMBL16658003 | 0.91 | BRD4 (0.69) | BRD4BRDT | |
| SCHEMBL29848989 | 0.91 | BRD4 (0.71) | BRD4BRDT | |
| SCHEMBL16650797 | 0.91 | BRD4 (0.71) | BRD4BRDT | |
| SCHEMBL16658113 | 0.87 | BRD4 (0.68) | BRD4 | |
| SCHEMBL16658126 | 0.86 | BRD4 (0.67) | BRD4 | |
| SCHEMBL17702534 | 0.85 | BRD4 (0.63) | BRD4BRDT | |
| SCHEMBL16657996 | 0.84 | BRD4 (0.64) | BRD4 | |
| SCHEMBL16658008 | 0.84 | BRD4 (0.57) | BRD4BRDT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240182490-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| US-11884680-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-20220315601-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2022-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182490-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | BRD4 5/4885BRDT 4/4885 |
| US-20220315601-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | BRD4 5/4885BRDT 4/4885 |
| US-11884680-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | BRD4 5/4885BRDT 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.